OBJECTIVE: Although fibroblast growth factor 23 (FGF23) has been implicated in the pathogenesis of cardiovascular disease, the relationship between FGF23 and cardiovascular disease has not been well characterized in the general population. The aim of this study was to determine whether serum FGF23 is independently associated with cardiovascular disease in older community-dwelling women. DESIGN AND METHODS: A cross-sectional design was used to examine the relationship between serum FGF23 and cardiovascular disease. The subjects consisted of a population-based sample of 659 women, aged 70-79 years, who participated in the Women's Health and Aging Studies in Baltimore, Maryland. Prevalent cardiovascular disease (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease) was assessed through diagnostic algorithms and physician adjudication. RESULTS: Of the 659 women, 185 (28.1%) had cardiovascular disease. Median (25th, 75th percentile) intact serumFGF23 was 34.6 (25.2, 46.2) pg/ml. The prevalence of cardiovascular disease in the lowest, middle, and highest tertile of serum FGF23 was 22.6, 24.9, and 36.7% respectively (P=0.002). Serum log FGF23 was associated with cardiovascular disease (odds ratio per 1 s.d. increase=1.23, 95% confidence interval 1.17, 1.30; P<0.0001) in a multivariable logistic regression model, adjusting for age, race, smoking, education, body mass index, cognition, diabetes, hypertension, physical activity, total cholesterol, high-density lipoprotein cholesterol, and renal function. CONCLUSION:Elevated serum FGF23 concentrations are independently associated with prevalent cardiovascular disease in older community-dwelling women. Further studies are needed to elucidate the potential biological mechanisms by which FGF23 may be involved in the pathogenesis of cardiovascular disease.
RCT Entities:
OBJECTIVE: Although fibroblast growth factor 23 (FGF23) has been implicated in the pathogenesis of cardiovascular disease, the relationship between FGF23 and cardiovascular disease has not been well characterized in the general population. The aim of this study was to determine whether serum FGF23 is independently associated with cardiovascular disease in older community-dwelling women. DESIGN AND METHODS: A cross-sectional design was used to examine the relationship between serum FGF23 and cardiovascular disease. The subjects consisted of a population-based sample of 659 women, aged 70-79 years, who participated in the Women's Health and Aging Studies in Baltimore, Maryland. Prevalent cardiovascular disease (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease) was assessed through diagnostic algorithms and physician adjudication. RESULTS: Of the 659 women, 185 (28.1%) had cardiovascular disease. Median (25th, 75th percentile) intact serum FGF23 was 34.6 (25.2, 46.2) pg/ml. The prevalence of cardiovascular disease in the lowest, middle, and highest tertile of serum FGF23 was 22.6, 24.9, and 36.7% respectively (P=0.002). Serum log FGF23 was associated with cardiovascular disease (odds ratio per 1 s.d. increase=1.23, 95% confidence interval 1.17, 1.30; P<0.0001) in a multivariable logistic regression model, adjusting for age, race, smoking, education, body mass index, cognition, diabetes, hypertension, physical activity, total cholesterol, high-density lipoprotein cholesterol, and renal function. CONCLUSION: Elevated serum FGF23 concentrations are independently associated with prevalent cardiovascular disease in older community-dwelling women. Further studies are needed to elucidate the potential biological mechanisms by which FGF23 may be involved in the pathogenesis of cardiovascular disease.
Authors: Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee Journal: Clin J Am Soc Nephrol Date: 2010-10-28 Impact factor: 8.237
Authors: Mehmet Kanbay; Mardare Nicoleta; Yusuf Selcoki; Mustafa Ikizek; Murat Aydin; Beyhan Eryonucu; Murat Duranay; Ali Akcay; Ferah Armutcu; Adrian Covic Journal: Clin J Am Soc Nephrol Date: 2010-06-24 Impact factor: 8.237
Authors: Suetonia C Palmer; Andrew Hayen; Petra Macaskill; Fabio Pellegrini; Jonathan C Craig; Grahame J Elder; Giovanni F M Strippoli Journal: JAMA Date: 2011-03-16 Impact factor: 56.272
Authors: Richard D Semba; Anne R Cappola; Kai Sun; Stefania Bandinelli; Mansi Dalal; Candace Crasto; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2011-04-07 Impact factor: 6.053
Authors: Amber L Fyfe-Johnson; Alvaro Alonso; Elizabeth Selvin; Julie K Bower; James S Pankow; Sunil K Agarwal; Pamela L Lutsey Journal: J Hypertens Date: 2016-07 Impact factor: 4.844
Authors: Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2013-02-26 Impact factor: 4.310
Authors: Marc G Vervloet; Arjan D van Zuilen; Annemieke C Heijboer; Piet M ter Wee; Michiel L Bots; Peter J Blankestijn; Jack F M Wetzels Journal: BMC Nephrol Date: 2012-04-24 Impact factor: 2.388
Authors: Samantha P Tippen; Megan L Noonan; Pu Ni; Corinne E Metzger; Elizabeth A Swallow; Spencer A Sacks; Neal X Chen; William R Thompson; Matthew Prideaux; Gerald J Atkins; Sharon M Moe; Matthew R Allen; Kenneth E White Journal: Bone Date: 2021-02-19 Impact factor: 4.398